Company Overview

Becton, Dickinson and Company (BD) is a global medical technology company that develops, manufactures, and sells a broad range of medical devices, laboratory equipment, diagnostics, and life science solutions. The company operates primarily within the medical technology, life sciences, and healthcare diagnostics industries, serving hospitals, laboratories, pharmaceutical companies, researchers, and healthcare providers. Its core revenue drivers are single-use medical devices, diagnostic systems, biosciences tools, and associated consumables, which generate recurring demand across clinical and research settings.

Founded in 1897, BD began as a manufacturer of syringes and medical instruments and steadily expanded through internal innovation and acquisitions. Over time, it evolved into a diversified healthcare technology company with a strong focus on safety-engineered devices, infection prevention, diagnostics, and data-enabled healthcare solutions. The company is recognized for its scale, broad product portfolio, and long-standing relationships with healthcare systems worldwide.

Business Operations

BD organizes its operations into three primary business segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical focuses on medication delivery solutions, including syringes, infusion technologies, and medication management systems. BD Life Sciences provides products for diagnostics, biosciences research, and clinical laboratories, including instruments, reagents, and software. BD Interventional delivers vascular, urology, oncology, and surgical specialty products, largely driven by minimally invasive technologies.

The company generates revenue through the sale of devices, instruments, and high-volume consumables, supported by service contracts and software solutions. BD operates manufacturing and R&D facilities globally and maintains extensive distribution networks in both developed and emerging markets. Its operations include numerous wholly owned subsidiaries and integrated businesses, with strategic collaborations across healthcare providers and research institutions.

Strategic Position & Investments

BD’s strategic direction emphasizes long-term growth through innovation, portfolio optimization, and targeted acquisitions that strengthen its position in higher-growth, higher-margin healthcare segments. The company has made major investments in diagnostics, biosciences automation, and data-driven healthcare solutions to support clinical decision-making and operational efficiency.

Notable acquisitions shaping BD’s current portfolio include C.R. Bard, which significantly expanded its interventional capabilities, and Edwards Lifesciences’ Critical Care product group, which enhanced BD’s advanced patient monitoring and vascular access offerings. BD continues to invest in emerging technologies such as molecular diagnostics, point-of-care testing, and advanced drug delivery systems, aligning its strategy with global trends in precision medicine and healthcare efficiency.

Geographic Footprint

BD is headquartered in Franklin Lakes, New Jersey, and operates on a global scale with a significant presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The United States represents its largest single market, while international markets account for a substantial and growing portion of total revenue.

The company maintains manufacturing, research, and commercial operations across multiple continents, supporting both local healthcare systems and global supply chains. BD’s international footprint enables it to serve diverse regulatory environments and healthcare infrastructures, while also positioning the company to benefit from long-term healthcare growth in emerging markets.

Leadership & Governance

BD is led by an experienced executive team focused on innovation, operational excellence, and long-term value creation for patients, customers, and shareholders. The company emphasizes a leadership philosophy centered on purpose-driven growth, patient safety, and ethical governance.

Key members of the leadership team include:

• Thomas Polen – Chairman, Chief Executive Officer, and President
• Christopher DelOrefice – Executive Vice President and Chief Financial Officer
• Gary DeFazio – Executive Vice President and President, BD Medical
• David Hickey – Executive Vice President and President, BD Interventional

The board and executive leadership oversee corporate strategy, capital allocation, and risk management, with governance practices aligned to U.S. public company standards and long-established healthcare industry regulations.